Clinical Trials Browser

Phase 1/2 × 64Cu-SARTATE × 1 year × Clear all

NCT04023331 2025-09-16

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Phase 1/2 Terminated

Neuroblastoma